- Home
- PAVS vs ALXO Comparison
PAVS vs ALXO Comparison
Compare PAVS & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVS
- ALXO
- Stock Information
- Founded
- PAVS 2004
- ALXO 2015
- Country
- PAVS United States
- ALXO United States
- Employees
- PAVS N/A
- ALXO N/A
- Industry
- PAVS Medicinal Chemicals and Botanical Products
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- PAVS Health Care
- ALXO Health Care
- Exchange
- PAVS Nasdaq
- ALXO Nasdaq
- Market Cap
- PAVS 90.2M
- ALXO 76.5M
- IPO Year
- PAVS 2019
- ALXO 2020
- Fundamental
- Price
- PAVS $1.37
- ALXO $0.62
- Analyst Decision
- PAVS
- ALXO Strong Buy
- Analyst Count
- PAVS 0
- ALXO 6
- Target Price
- PAVS N/A
- ALXO $4.14
- AVG Volume (30 Days)
- PAVS 10.0K
- ALXO 1.4M
- Earning Date
- PAVS 01-01-0001
- ALXO 03-06-2025
- Dividend Yield
- PAVS N/A
- ALXO N/A
- EPS Growth
- PAVS N/A
- ALXO N/A
- EPS
- PAVS N/A
- ALXO N/A
- Revenue
- PAVS $6,544,819.00
- ALXO N/A
- Revenue This Year
- PAVS N/A
- ALXO N/A
- Revenue Next Year
- PAVS N/A
- ALXO N/A
- P/E Ratio
- PAVS N/A
- ALXO N/A
- Revenue Growth
- PAVS N/A
- ALXO N/A
- 52 Week Low
- PAVS $0.32
- ALXO $0.59
- 52 Week High
- PAVS $1.85
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- PAVS 44.74
- ALXO 31.52
- Support Level
- PAVS $1.33
- ALXO $0.65
- Resistance Level
- PAVS $1.40
- ALXO $0.72
- Average True Range (ATR)
- PAVS 0.03
- ALXO 0.07
- MACD
- PAVS -0.01
- ALXO -0.00
- Stochastic Oscillator
- PAVS 25.00
- ALXO 6.09
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.